These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 21331764

  • 1. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
    Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R.
    Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
    [Abstract] [Full Text] [Related]

  • 4. [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
    Huang FK, Shi Z.
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):808-12. PubMed ID: 21223684
    [Abstract] [Full Text] [Related]

  • 5. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV, Hicks MD, Mull L, Foreman B.
    J Gastrointest Cancer; 2007 Nov; 38(2-4):154-6. PubMed ID: 19089671
    [Abstract] [Full Text] [Related]

  • 6. Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
    Kim DH, Jeong YI, Chung CW, Kim CH, Kwak TW, Lee HM, Kang DH.
    Int J Nanomedicine; 2013 Nov; 8():1697-711. PubMed ID: 23658488
    [Abstract] [Full Text] [Related]

  • 7. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y, Jiang H, Gao H, Kong J, Zhang P, Hu S, Shi B, Zhang P, Yao M, Li Z.
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [Abstract] [Full Text] [Related]

  • 8. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W.
    J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
    Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R.
    Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):893-905. PubMed ID: 21487100
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC.
    Neurosci Lett; 2010 Jul 12; 478(3):165-70. PubMed ID: 20470863
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 15. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G, Wang M, Hyslop T, Wang Z, Carr BI.
    Int J Cancer; 2010 Dec 15; 127(12):2949-58. PubMed ID: 21351273
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC.
    J Cell Mol Med; 2009 Aug 01; 13(8B):2673-2683. PubMed ID: 19220580
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.